Table 2 Antibody concentrations stratified by the clinical classification
From: The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
Clinical Classification | Sum | P value | |||
|---|---|---|---|---|---|
Mild | Regular | Severe | |||
N | 1 | 34 | 6 | 41 | – |
Age | 25 | 52.5 (39.8, 64.8) | 67.0 (55.5,71.5) | 60.0 (39.5,67.5) | 0.091 |
Male | 0.0% | 50.0% | 33.3% | 51.2% | 0.366 |
Concentration of COVID-19 IgG (AU/ml) | 9.1 | 22.2 (3.9, 89.4) | 157.9 (28.8190.7) | 30.6 (8.4, 129.4) | 0.056 |
Seroprevalence of COVID-19 IgG | 100.0% | 70.6% | 100.0% | 65.9% | 0.256 |
Concentration of COVID-19 IgM (AU/ml) | 8.17 | 27.9 (4.4, 145.6) | 29.7 (8.6, 188.6) | 25.5 (5.2152.7) | 0.677 |
Seroprevalence of COVID-19 IgM | 100.0% | 73.5% | 83.3% | 75.6% | 0.742 |